Hoesli RC, et al. - In this case series involving 154 patients, researchers described the rates of dysplasia, development of malignant lesions, and adverse events correlated with use of intralesional cidofovir injections as adjuvant treatment for recurrent respiratory papillomatosis (RRP) vs patients treated without adjuvant cidofovir. Findings suggested no association of intralesional injection of cidofovir with increased risk of dysplasia or carcinoma or a statistically significant increase in complications. In patients with a high burden of disease with RRP, intralesional cidofovir injections can be considered for adjuvant therapy.